Leerink Partners Says Exelixis (EXEL) Sell-Off on ESMO Abstracts 'Overdone'
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Exelixis (EXEL) 30-day volatility at 106 compared to 60 from a month ago
September 28, 2016 12:19 PM EDTExelixis (NASDAQ: EXEL) is recently down 17% on cabozantinib and Opdivo data concerns. 30-day call option implied volatility of 106 compares to volatility of 60 from a month ago.
... MoreExelixis (EXEL) call volume and volatility spikes as shares fall 17%
September 28, 2016 11:55 AM EDTExelixis (NASDAQ: EXEL) October 14 and 16 calls are active on total call volume of 9K contracts (3K puts). October call option implied volatility is at 99, November is at 82; compared to its 52 week range of 46 to 98.
... MoreUPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data
September 28, 2016 11:46 AM EDT(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)
Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.
According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.
... More